Spire Healthcare Group (LON:SPI) had its target price dropped by investment analysts at JPMorgan Chase & Co. from GBX 339 ($4.68) to GBX 293 ($4.05) in a report issued on Monday. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective would indicate a potential upside of 32.58% from the stock’s current price.
Other analysts also recently issued reports about the stock. Liberum Capital upped their price objective on shares of Spire Healthcare Group from GBX 270 ($3.73) to GBX 275 ($3.80) and gave the stock a “hold” rating in a report on Friday, January 26th. Barclays decreased their price objective on shares of Spire Healthcare Group from GBX 270 ($3.73) to GBX 255 ($3.52) and set an “equal weight” rating for the company in a report on Monday, March 5th. Numis Securities reaffirmed an “add” rating and set a GBX 296 ($4.09) price objective on shares of Spire Healthcare Group in a report on Tuesday, January 16th. Jefferies Group raised shares of Spire Healthcare Group to a “buy” rating and upped their price objective for the stock from GBX 259 ($3.58) to GBX 290 ($4.01) in a report on Wednesday, January 17th. Finally, Berenberg Bank raised shares of Spire Healthcare Group to a “buy” rating and upped their price objective for the stock from GBX 270 ($3.73) to GBX 310 ($4.28) in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. Spire Healthcare Group presently has an average rating of “Hold” and an average target price of GBX 295.57 ($4.08).
Spire Healthcare Group (LON:SPI) traded down GBX 3 ($0.04) during midday trading on Monday, hitting GBX 221 ($3.05). 931,014 shares of the company traded hands, compared to its average volume of 1,570,000. The company has a market cap of $886.39 and a P/E ratio of 5,525.00. Spire Healthcare Group has a fifty-two week low of GBX 206.40 ($2.85) and a fifty-two week high of GBX 362.10 ($5.00).
In related news, insider Justin Ash bought 46,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 6th. The stock was purchased at an average cost of GBX 215 ($2.97) per share, for a total transaction of £99,975 ($138,125.17).
ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/03/12/spire-healthcare-group-spi-given-new-gbx-293-price-target-at-jpmorgan-chase-co.html.
About Spire Healthcare Group
Spire Healthcare Group plc is a United Kingdom-based independent hospital group. The Company provides in-patient, daycase and out-patient care from approximately 40 hospitals, 10 clinics and over two specialist care centers across the United Kingdom. The Company also owns and operates a sports medicine, physiotherapy and rehabilitation brand, Perform, and a screening service, Lifescan, as well as national pathology services.
Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.